Free tool
FAERS Monitor: Zeposia
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209899 or its brand name (Zeposia, Ozanimod Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
8,477
Serious
2,297
27% of reports
Hospitalization
631
Death reported
91
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue789
- multiple sclerosis relapse595
- drug ineffective553
- headache526
- product dose omission issue381
- dizziness356
- nausea288
- diarrhoea267
- colitis ulcerative263
- pain259
- back pain218
- fall197
- adverse event193
- multiple sclerosis181
- dyspnoea160
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 243 |
| 2021 | 1,903 |
| 2022 | 1,705 |
| 2023 | 1,533 |
| 2024 | 1,481 |
| 2025 | 995 |
| 2026 | 617 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,682 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| multiple sclerosis relapseSignal | 595 | 21.7 | 20.1 | 11,676 |
| colitis ulcerativeSignal | 263 | 14.7 | 13.0 | 3,326 |
| multiple sclerosisSignal | 181 | 9.4 | 8.2 | 1,352 |
| adverse eventSignal | 193 | 5.2 | 4.5 | 653 |
| product dose omission issueSignal | 381 | 3.2 | 2.9 | 588 |
| fatigueSignal | 789 | 2.5 | 2.4 | 746 |
| back painSignal | 218 | 2.3 | 2.0 | 166 |
| headacheSignal | 526 | 2.1 | 1.9 | 304 |
| dizziness | 356 | 1.8 | 1.6 | 122 |
| fall | 197 | 1.5 | 1.3 | 29 |
| pain | 259 | 1.0 | 0.9 | 0 |
| drug ineffective | 553 | 1.0 | 1.0 | 1 |
| diarrhoea | 267 | 1.0 | 0.9 | 0 |
| nausea | 288 | 0.9 | 0.8 | 3 |
| dyspnoea | 160 | 0.7 | 0.6 | 21 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.